Press Releases
Press Releases
-
March 30, 2020
Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer -
March 19, 2020
U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection -
March 11, 2020
New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020 -
March 10, 2020
Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study -
March 10, 2020
Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations -
March 9, 2020
New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults -
March 2, 2020
Gilead to Acquire Forty Seven for $4.9 Billion -
February 26, 2020
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 -
February 19, 2020
Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center -
February 18, 2020
Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020